Pharmaceutical disbursements from India to the United States are poised for significant expansion by 2025. This phenomenon is driven by a confluence of factors, including India's recognized reputation as a global fabrication hub for affordable medicines and the increasing requirement for quality healthcare solutions in the USA. Despite this, naviga